Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers

Journal of Virological Methods

Volumn 149, Issue 1, 2008, Pages 76-84

  Kim, Jong Kee ^a   Lee, Hyeon Ji ^a   Lee, Young Jo ^a   Chun, Jong Yoon ^a   Lee, In Kyoung ^a   Lim, Young Suk ^b   Suh, Dong Jin ^b   Ko, Sun Young ^b   Kim, Myeong Hee ^b   Oh, Heung Bum ^b  

^a Seegene Institute of Life Sciences   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; HBV; Lamivudine resistance; Seeplex Lami DR assay

Indexed keywords

LAMIVUDINE;

ARTICLE; CODON; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS MUTATION;

ANTIVIRAL AGENTS; DNA PRIMERS; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MUTATION; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

HEPATITIS B VIRUS;

EID: 40849101514     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.01.003     Document Type: Article

References (38)

1. Aberle S.W., Kletzmayr J., Watschinger B., Schmied B., Vetter N., and Puchhammer-Stockl E. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J. Clin. Microbiol. 39 (2001) 1972-1974
2. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., Brown N., and Condreay L.D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 (1998) 1670-1677
3. Allen M.I., Gauthier J., DesLauriers M., Bourne E.J., Carrick K.M., Baldanti F., Ross L.L., Lutz M.W., and Condreay L.D. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J. Clin. Microbiol. 37 (1999) 3338-3347
4. Bowden S., Bartholomeusz A., and Locarnini S. Lamivudine resistant occult HBV: implications for public health?. J. Hepatol. 38 (2003) 526-528
5. Chieochansin T., Chutinimitkul S., Payungporn S., Theamboonlers A., Tangkijvanich P., Komolmit P., and Poovorawan Y. Rapid detection of lamivudine-resistant hepatitis B virus mutations by PCR-based methods. Tohoku J. Exp. Med. 210 (2006) 67-78
6. Chun J.Y., Kim K.J., Hwang I.T., Kim Y.J., Lee D.H., Lee I.K., and Kim J.K. Dual priming oligonucleotide system for the multiplex detection of respiratory viruses and SNP genotyping of CYP2C19 gene. Nucleic Acids Res. 35 (2007) e40
7. Delaney W.E.t., Yang H., Westland C.E., Das K., Arnold E., Gibbs C.S., Miller M.D., and Xiong S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 77 (2003) 11833-11841
8. Fu L., and Cheng Y.C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in l(-)SddC (3TC) resistance. Biochem. Pharmacol. 55 (1998) 1567-1572
9. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., Laras A., and Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32 (2000) 847-851
10. Hong S.P., Kim N.K., Hwang S.G., Chung H.J., Kim S., Han J.H., Kim H.T., Rim K.S., Kang M.S., Yoo W., et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J. Hepatol. 40 (2004) 837-844
11. Hussain M., and Lok A.S. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J. Viral. Hepat. 6 (1999) 183-194
12. Jang H., Cho M., Heo J., Kim H., Jun H., Shin W., Cho B., Park H., and Kim C. Oligonucleotide chip for detection of Lamivudine-resistant hepatitis B virus. J. Clin. Microbiol. 42 (2004) 4181-4188
13. Jardi R., Buti M., Rodriguez-Frias F., Cotrina M., Costa X., Pascual C., Esteban R., and Guardia J. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J. Virol. Methods 83 (1999) 181-187
14. Kirishima T., Okanoue T., Daimon Y., Itoh Y., Nakamura H., Morita A., Toyama T., and Minami M. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J. Hepatol. 37 (2002) 259-265
15. Lai C.L., Ching C.K., Tung A.K., Li E., Young J., Hill A., Wong B.C., Dent J., and Wu P.C. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25 (1997) 241-244
16. Lai C.L., Dienstag J., Schiff E., Leung N.W., Atkins M., Hunt C., Brown N., Woessner M., Boehme R., and Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36 (2003) 687-696
17. Lampertico P., Vigano M., Manenti E., Iavarone M., Lunghi G., and Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42 (2005) 1414-1419
18. Liaw Y.F. Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how?. Hepatology 45 (2007) 266-268
19. Liaw Y.F., Chien R.N., Yeh C.T., Tsai S.L., and Chu C.M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30 (1999) 567-572
20. Lim Y.S., and Suh D.J. Current antiviral therapy for chronic hepatitis B. J. Korean Med. Sci. 19 (2004) 489-494
21. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
22. Lok A.S., Zoulim F., Locarnini S., Mangia A., Niro G., Decraemer H., Maertens G., Hulstaert F., De Vreese K., and Sablon E. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J. Clin. Microbiol. 40 (2002) 3729-3734
23. Mahoney F.J. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin. Microbiol. Rev. 12 (1999) 351-366
24. Mast E., and Alter M.J. Epidemiology of viral hepatitis: an overview. Semin. Virol. 8 (1993) 391-399
25. Merle P., and Trepo C. Therapeutic management of hepatitis B-related cirrhosis. J. Viral. Hepat. 8 (2001) 391-399
26. Niesters H.G., De Man R.A., Pas S.D., Fries E., and Osterhaus A.D. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J. Med. Microbiol. 51 (2002) 695-699
27. Ou Z.Y., Liu N., Chen C.J., Cheng G., and He Y.S. Rapid and accurate genotyping of YMDD motif variants in the hepatitis B virus genome by an improved reverse dot blot method. J. Clin. Microbiol. 43 (2005) 5685-5689
28. Papatheodoridis G.V., Dimou E., Laras A., Papadimitropoulos V., and Hadziyannis S.J. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 36 (2002) 219-226
29. Pas S.D., de Man R.A., Fries E., Osterhaus A.D., and Niesters H.G. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation. J. Clin. Virol. 25 (2002) 63-71
30. Pillay D., Bartholomeusz A., Cane P., Mutimer D., Schinazi R.F., and Locarnini S. Mutation in the hepatitis B virus DNA polymerase associated with antiviral resistance. Int. Antivir. News 6 (1998) 167-169
31. Rapti I., Dimou E., Mitsoula P., and Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45 (2007) 307-313
32. Sablon E., and Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int. J. Med. Sci. 2 (2005) 8-16
33. Seigneres B., Pichoud C., Martin P., Furman P., Trepo C., and Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36 (2002) 710-722
34. Stuyver L., Van Geyt C., De Gendt S., Van Reybroeck G., Zoulim F., Leroux-Roels G., and Rossau R. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J. Clin. Microbiol. 38 (2000) 702-707
35. Stuyver L.J., Locarnini S.A., Lok A., Richman D.D., Carman W.F., Dienstag J.L., and Schinazi R.F. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33 (2001) 751-757
36. Wang J.H., Lu S.N., Lee C.M., Lee J.F., and Chou Y.P. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand. J. Gastroenterol. 37 (2002) 366-369
37. Wightman F., Walters T., Ayres A., Bowden S., Bartholomeusz A., Lau D., Locarnini S., and Lewin S.R. Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. J. Clin. Microbiol. 42 (2004) 3809-3812
38. Zoulim F. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. Semin. Liver Dis. 22 Suppl. 1 (2002) 23-31